Skip to main content
. 2022 Mar;192(3):564–578. doi: 10.1016/j.ajpath.2021.11.013

Table 7.

Immunohistochemical Staining for ApoE in Amygdala Sections from a Convenience Sample of 14 Cases from the University of Kentucky AD Research Center Biobank

Case # Age, years Sex Final MMSE score Braak NFT stage CERAD neuritic amyloid plaque severity APOE allele status ApoE MS result ApoE stained astrocytes ApoE IHC-stained AD-type pathology
1068 92 F 22.5 VI Moderate 2/3 51.1 + +
1298 96 F 24 VI Severe 2/3 36.4 ++ ++
5384 87 M 0 V Moderate 3/3 151.9 ++ +
1096 84 M 23 VI Severe 3/3 151.4 ++ ++
1309 83 F 30 II None 3/3 0 +++
1106 79 M 29 II Severe 3/3 44.1 + ++
1053 90 F 22.5 VI Severe 3/3 85.9 ++ ++
5372 94 M 24 V Severe 3/3 113.1 ++ ++
5394 64 F 6 VI Severe 3/4 248.5 + +++
1101 86 F 7 VI Severe 3/4 374.5 + ++
1052 80 F 19 VI Moderate 3/4 348.9 + +++
1035 84 F 19 V Severe 3/4 46.2 + +++
1037 82 M 17.5 VI Severe 3/4 253.7 + +++
5361 87 M 13 V Severe 4/4 59 + +++

F, female; M, male; AD, Alzheimer disease; ApoE, Apolipoprotein E; IHC, immunohistochemistry; MCI, mild cognitive impairment; MMSE, Mini–Mental State Examination; MS, mass spectrometry; NFT, neurofibrillary tangle.

ApoE IHC staining of cells resembling reactive astrocytes in amygdala: minimal (+), moderate (++), and widespread (+++).

AD neuropathologic change features stained with ApoE IHC in amygdala: none (–); a minimal number of focal senile plaque-like structures (+), moderate densities of senile-plaque–like structures (++), or widespread senile plaques with some structures that resemble NFTs (+++).